A portion of the disclosure of this patent document contains or may contain material which is subject to copyright protection. The copyright owner has no objection to the photocopy reproduction by anyone of the patent document or the patent disclosure in exactly the form it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever.
The present disclosure relates in general to a system and methods for applying therapeutic energy to a tissue mass, and in particular to an apparatus for applying x-ray energy and laser energy to a tumor mass and monitoring the dose of x-ray energy and temperature of the tissue adjacent to the tumor mass.
Percutaneous in situ or on-site laser therapy treatment of tissue such as tumors and in particular malignant breast tumors can be more readily performed today because tissue abnormalities such as tumors are being detected at earlier stages. Moreover, other treatment techniques can be performed in similarly early stages of the development of tissue abnormalities, such as the application of x-ray energy to a tissue abnormality. Tissue abnormalities such as breast cancer and other cancers or tumors detected early in development can be effectively treated or destroyed using an ablative agent such as laser energy without conventional surgery.
Interstitial laser treatments of tissue (such as tumors) including malignant tumors (such as breast, liver, brain, and neck tumors), have been in development for more than a decade. For example, U.S. Pat. No. 5,169,396, U.S. Pat. No. 5,222,953, U.S. Pat. No. 5,569,240, U.S. Pat. No. 5,853,366, U.S. Pat. No. 6,603,988, U.S. Pat. No. 6,701,175, U.S. Pat. No. 6,865,412, U.S. Pat. No. 7,041,109, and U.S. Pat. No. 7,171,253 disclose various apparatus and methods for applying laser energy directly to a tissue abnormality. Certain of these patents disclose a laser source for generating ablative laser energy to be applied to the tissue abnormality. Certain of these patents also disclose thermal probes including thermistors for detecting the temperature of tissue adjacent to tissue abnormalities.
In certain known treatment regimens, interstitial laser therapy is followed or preceded by chemotherapy, radiation therapy, or both. Currently available radiation therapy techniques require invasive steps beyond the minimally invasive techniques for performing interstitial laser therapy. For example, one radiation therapy technique includes creating an incision to enable radioactive seeds to be deposited at or near the tissue abnormality to be treated.
Furthermore, in certain other known treatment regimes, an apparatus for delivering energy to a tissue mass to be treated (such as a tumor mass) includes a catheter inserted in the vicinity of the tissue mass. In certain of such treatment regimes, the catheter is configured to maintain a cavity created as the tissue mass to be treated is destroyed (i.e., as the tissue mass is ablated). For example, in certain treatment regimes, the catheter includes a balloon which is inflated during treatment to maintain the cavity created by ablation of the tissue mass.
There is a need for a system to enable an integrated delivery modality that can deliver radiation to a treatment site in a controlled, minimally invasive way. There is a further need for devices for facilitating interstitial brachytherapy in a minimally invasive way. There is a further need for a therapeutic system including a plurality of components for applying therapeutic laser energy and therapeutic x-ray energy without removing or inserting one or more additional percutaneous components. There is a further need for a therapeutic system which enables delivery of radiation to a treatment site without the use of a catheter or balloon to maintain a cavity formed during treatment.
Various embodiments of the therapeutic system disclosed herein enable an operator to conduct either interstitial laser therapy, brachytherapy, or both interstitial laser therapy and brachytherapy on the same tissue of interest. The disclosed system includes two general categories of components. The first category includes components usable to perform both interstitial laser therapy and brachytherapy. The second category includes components usable to perform either interstitial laser therapy or brachytherapy, but not both. For purposes of brevity of this application, the tissue of interest will sometimes be referred to as the “treated tissue” and will sometimes be referred to as the “tumor.” It should be appreciated that in different embodiments, the therapeutic energy system disclosed enables therapeutic energy to be applied to tissue other than tumors, or to tumors in locations of the body other than the breasts.
In one embodiment, the first category of components of the therapeutic system disclosed herein (i.e., the components usable to perform both interstitial laser therapy and brachytherapy) includes an energy probe configured to be positioned in the tumor, a sensing probe configured to detect a plurality of temperatures and a plurality of dosage amounts, at least one probe holder configured to position the energy probe and the sensing probe with respect to a stereotactic imaging device, and a computer configured to (a) control the amount of laser energy applied to the tumor; (b) control the amount of x-ray energy applied to the tumor; (c) monitor the temperature of the tissue adjacent to the tumor based on a plurality of received signals indicating a plurality of detected temperatures; and (d) monitor the dosage applied to the tumor mass based on a plurality of received signals indicating a plurality of detected dosage amounts. In this embodiment, the second category of components (i.e., the components usable to perform either interstitial laser therapy or brachytherapy but not both) includes a laser energy source, an x-ray energy source, an optical fiber configured to be connected to the laser energy source and to be removably inserted in the energy probe, an optical fiber configured to be connected to the x-ray energy source and to be removably inserted in the energy probe, and at least one controller configured to (a) receive a plurality of electrical signals from a plurality of sensors; (b) convert the received electric signals into a plurality of temperatures and a plurality of dosage amounts; and (c) send a plurality of signals indicating the converted temperatures and dosage amounts to the computer of the first category of components.
In one embodiment, the first category of components and the second category of components of the therapeutic system disclosed herein enable an operator to perform interstitial laser therapy before performing brachytherapy. Specifically, the therapeutic system disclosed enables an operator to configure the components of the first category of components with the interstitial laser therapy-specific components of the second category of components to apply controlled amounts therapeutic laser energy directly to a tumor and to monitor the temperature of the tissue adjacent to the tumor. In this embodiment, the therapeutic system then enables the operator to replace the interstitial laser therapy-specific components of the second category of components with the brachytherapy-specific components and to apply controlled amounts of therapeutic x-ray energy and monitor the dose(s) applied to the tumor.
In an alternative embodiment, the therapeutic system disclosed herein enables an operator to perform brachytherapy prior to performing interstitial laser therapy by utilizing the components of the first category of components with the brachytherapy-specific components of the second category of components to apply x-ray energy until a specific dosage is achieved. In this embodiment, the disclosed system enables the operator to remove the brachytherapy-specific components and utilize the interstitial laser therapy-specific components to apply laser energy until a specified tissue temperature is achieved for tissue adjacent to the tumor mass.
In one embodiment, the components of the system disclosed herein do not include any device or mechanism for maintaining a cavity formed during application of energy to treated tissue. In one such embodiment, the energy probe is configured such that the diameter of the energy probe is substantially constant throughout the length of the energy probe. In one embodiment, the diameter of the probe is relatively small compared to the diameter of the treated tissue. In this embodiment, the structure of the probe itself does not provide an artificial boundary to a cavity formed around the treated tissue. Thus, it should be appreciated that the energy probe in one embodiment is configured not to maintain a cavity formed during application of therapeutic energy—that is, the energy probe does not include a device, such as an inflatable balloon, for maintaining a cavity during treatment.
In one embodiment, the system disclosed herein enables a surgical excision of tissue, such as a lumpectomy, to be performed coincident to application of therapeutic energy to the tissue. In this embodiment, the disclosed system enables an operator to enhance or improve upon results obtainable using such known surgical excision techniques, increasing an overall effectiveness of the treatment of the tissue.
It should be appreciated that combining the components of the first category of components with the brachytherapy-specific components of the second category of components enables the operator to accurately deliver x-ray energy to a tumor. It should be further appreciated that combining the components of the first category of components with the interstitial laser therapy-specific components of the second category of components enables the operator to accurately deliver laser energy to the tumor.
It is therefore an advantage of the present disclosure to provide a therapeutic system for performing interstitial laser therapy and also for performing interstitial brachytherapy wherein the temperature of the tissue adjacent to the tumor mass and the dosage applied to the tumor are respectively monitored.
It is a further advantage of the present disclosure to provide a system for performing interstitial laser therapy and brachytherapy wherein the system includes a plurality of components which are usable to perform both interstitial laser therapy and brachytherapy.
It is a further advantage of the present disclosure to provide a system for performing interstitial laser therapy and brachytherapy which does not require an additional structure, such as a balloon, for maintaining a cavity during treatment.
It is a further advantage of the present disclosure to provide a system for performing interstitial laser therapy and brachytherapy which is usable coincident to known techniques for surgical excision of tissue to enhance the results of a treatment.
It is a further advantage of the present disclosure to provide a therapeutic energy system to enable an operator to apply laser energy and x-ray energy to tissue of interest which saves operator time, saves money on the cost of the components of the disclosed system, decreases patient discomfort, decreases the number of components to be sterilized, increases the accuracy of the point where therapeutic energy is delivered, reduces the number of needle sticks, increases the precision with which amounts of therapeutic energy are applied to tissue of interest such as a tumor mass, and increases the options available to treat tissue of interest such as a tumor mass.
Additional features and advantages of the present invention are described in, and will be apparent from, the following Detailed Description of Exemplary Embodiments and the figures.
Referring now to
Referring first to items of category one, the disclosed system includes a plurality of components usable to perform both interstitial laser therapy and brachytherapy. As illustrated, the components of category one includes an energy probe 100, a sensing probe 102, and at least one probe holder 50. Category one system also includes a computer system 110 configured to receive a plurality of signals indicating quantities of applied energy, and configured to send a plurality of signals indicating changes in the amount of energy applied based on the received signals indicating quantities of applied energy. In the illustrated embodiment, the probe holder 50 is configured to position the energy probe 100 and the sensing probe 102 with respect to a tumor mass 10 of a body part 1 such as a breast. As illustrated, the probe holder 50 is configured to position the energy probe 100 such that the tip of the energy probe 100 is in the center of the tumor mass 10. The probe holder 50 is configured to position the sensing probe 102 such that the plurality of sensors 102d of the sensing probe are adjacent to the tumor mass 10 to sense indicators of applied therapeutic energy of tissue adjacent to the tumor mass 10.
The components included in category two of the disclosed therapeutic system include components usable to perform either interstitial laser therapy or brachytherapy, but not both. In the illustrated embodiment, category two includes a plurality of energy sources such as a laser energy source 140 and an x-ray energy source 150. It should be appreciated that the laser energy source 140 is configured to emit laser energy into an appropriate optical fiber configured to deliver laser energy. It should be further appreciated that the x-ray energy source 150 is configured to emit x-ray energy into an appropriate optical fiber configured to deliver x-ray energy.
Category two also includes a plurality of optical fibers such as a laser optical fiber 104 and an x-ray optical fiber 105. In the illustrated embodiment, the laser optical fiber 104 is configured to be removably attachable to the laser energy source 140. The laser optical fiber 104 is further configured to transmit laser energy along the length of the laser optical fiber and to deliver the energy as light energy at the tip of the laser optical fiber. Similarly, the x-ray optical fiber 105 is configured to be removably attachable to the x-ray energy source 150. The x-ray optical fiber 105 is configured to transmit any x-ray energy emitted by the x-ray energy source 150 along the length of the fiber and to emit the energy as x-ray energy at the tip of the x-ray optical fiber 105.
The components of category two further include a plurality of controllers configured to convert electrical signals to values indicating an amount of energy applied to the tumor mass 10. In the illustrated embodiment, the therapeutic system includes two controllers including a thermistor controller 240 and a dosimeter controller 250. In this embodiment, the thermistor controller 240 is configured to convert a plurality of electrical signals indicating a plurality of detected resistances into a plurality of temperatures. The dosimeter controller 250 is similarly configured to convert a plurality of electrical signals indicating a plurality of changes in charge difference between a plurality of pairs of electrodes of a plurality of dosimeters into a plurality of dosage amounts.
Referring still to
In the illustrated embodiment, the energy probe 100 is configured to be positioned in the tumor mass 10 of the body part to be treated 1 using the at least one probe holder 50. The sensing probe 102 is configured to be positioned relative to the energy probe 100 using the at least one probe holder 50.
The energy probe 100 is configured to be connected to the thermistor controller 240 and the dosimeter controller 250 using the energy probe wire 100c. In this embodiment, the energy probe 100 includes at least one thermistor 100e and at least one dosimeter 100e positioned on the tip of the probe 100 and configured to detect a tissue temperature or a dosage amount of the tumor mass 10. It should be appreciated that in various embodiments, the energy probe 100 does not include any sensor 100e such as a thermistor or a dosimeter. In these embodiments, the energy probe does not include an energy probe wire 100c and is not configured to be connected to the thermistor controller or the dosimeter controller.
In the illustrated embodiment, the energy probe 100 is configured to have a substantially constant diameter throughout the length of the probe 100. In the illustrated embodiment, the diameter of the energy probe 100 is relatively small compared to a diameter of the tumor mass 10. Thus, it should be appreciated that in the illustrated embodiment, the energy probe 100 is not configured to maintain a cavity approximating the shape and size of the tumor mass 10 during application of therapeutic energy to the tumor mass 10. That is, the energy probe 100 is not dimensioned (and does not include an additional structure, such as a balloon) to maintain a cavity within the body part 1 approximating the dimensions of the tumor mass 10 to which therapeutic energy is applied.
In one embodiment, a stylet 100b (not shown) is configured to be removable from the cannula 100a after the stylet has been inserted in the tumor mass 10. In this embodiment, removing the stylet 100b enables an optical fiber to be inserted in the energy probe 100. In one embodiment, the laser optical fiber 104 is configured to be inserted in the energy probe 100 after having been attached to the laser energy source 140. In this embodiment, the laser energy probe is configured to deliver laser energy emitted by the laser energy source 140 to the tumor mass 10 in which the energy probe 100 is positioned. In another embodiment, the x-ray optical fiber 105 is configured to be inserted in the energy probe 100 after having been attached to the x-ray energy source 150. In this embodiment, the x-ray optical fiber 105, already connected to the laser energy source, is configured to deliver x-ray energy emitted by the x-ray energy source 150 to the tumor mass 10 in which the energy probe is positioned. It should be appreciated that in one embodiment, the energy probe 100 is configured such that only one of the laser optical fiber 104 and the x-ray optical fiber 105 is insertable in the energy probe 100 at once.
The sensing probe 102 is configured to be connected to the plurality of controllers such as the thermistor controller 240 and the dosimeter controller 250. In the illustrated embodiment, the sensing probe 102 is configured to so connect to the plurality of controllers using the sensing probe wire 102a. As discussed above, the sensing probe wire 102a is configured to carry electrical signals from the plurality of sensors 102d of the sensing probe to the controllers 240 or 250. In one embodiment, the sensing probe wire 102a is also configured to carry a plurality of signals from the dosimeter controller 250 to the dosimeters 102d including energy to maintain charge differences between a plurality of pairs of electrodes the dosimeters.
The computer system 110 is a component of category one, meaning that it is configured to be usable to perform both interstitial laser therapy and brachytherapy. In one embodiment, the computer system 110 includes at least one microprocessor, at least one memory device, at least one display device, at least one input device, at least one interface device for receiving a plurality of signals from a plurality of sensing controllers, and at least one interface device for sending a plurality of signals to a plurality of energy sources. In the illustrated embodiment, the computer system 110 is connected to the thermistor controller 240 and the dosimeter controller 250, and is further connected to the laser energy source 140 and the x-ray energy source 150. In this embodiment, the computer is configured to receive a plurality of signals from the thermistor controller 240 indicating temperatures sensed by the plurality of thermistors of the sensing probe 102. The computer 110 is also configured to receive a plurality of signals from the dosimeter controller 250 indicating dosages detected by the plurality of dosimeters of the sensing probe.
The computer 110 is further configured in one embodiment to store data indicative of the received signals to track the progress of interstitial laser therapy and brachytherapy performed with the disclosed therapeutic system. In one embodiment, the computer system 110 is configured to store each received temperature in a database associated with a patient having the body part 1, and is further configured to store each received dosage amount in the same database. In a further embodiment, the computer 110 is configured to display on the at least one display device a graphical representation of the received signals indicating a plurality of temperatures and a plurality of dosage amounts. In various embodiments, the computer is configured to display a bar graph wherein each bar indicates a temperature of a single thermistor or a dosage of a single dosimeter.
In one embodiment, the computer 110 is further configured to send a plurality of signals to the plurality of energy sources including the laser energy source 140 and the x-ray energy source 150 to change the amount of energy emitted. In one embodiment, if the temperature detected by one or more of the plurality of thermistors of the sensing probe 102 exceeds a predetermined maximum temperature, the computer 110 is configured to send a signal to the laser energy source 140 to cause the laser energy source to stop emitting laser energy. In another embodiment, if a dosage amount detected by one of the dosimeters of the sensing probe 102 exceeds a predetermined maximum dosage amount, the computer 110 is configured to send a signal to the x-ray energy source 150 to cause the x-ray energy source to stop emitting x-ray energy. In various embodiments, once the predetermined maximum temperature or the predetermined maximum dosage amount has been detected, the computer is configured to continue receiving signals indicating temperatures or dosages. In one embodiment, the computer is configured to send a signal to cause the laser energy source 140 to resume generating laser energy when at least one of the thermistors of the sensing probe 102 indicates a temperature below a predefined resume treatment temperature.
It should be appreciated that in various embodiments, one or more components illustrated as belonging to category one in
In various embodiments, one or more components of category two are configured to be usable to perform both interstitial laser therapy and brachytherapy. For example, in one embodiment the laser optical fiber 104 and the x-ray optical fiber 105 are a single energy optical fiber. In this embodiment, the energy optical fiber and is configured to transmit laser energy and x-ray energy to the tumor mass 10. It should be appreciated that with a single energy optical fiber, an operator in one embodiment removes the energy optical fiber form the laser energy source and connects it to the x-ray energy source, or vice versa, to switch from between performing interstitial laser therapy and brachytherapy.
In various embodiments, the laser energy source 140 and the x-ray energy source 150 are enclosed in a single energy source enclosure. In this embodiment, the laser optical fiber 104 and the x-ray optical fiber 105 are configured to be attachable to different connectors on the same energy source enclosure. In a further embodiment, the combined energy source enclosure includes a single energy connector for connecting the x-ray optical fiber and the laser optical fiber. In this embodiment, an electro-mechanical mechanism within the combined energy source enclosure is configured to switch from emitting laser energy to x-ray energy. In one embodiment, this switch is actuated by a signal sent from the computer 110.
To begin performing either interstitial laser therapy or brachytherapy using the disclosed therapeutic system, an operator positions the components of category one. Referring to process 600a of
As discussed above, the therapeutic system disclosed herein enables an operator to perform both interstitial laser therapy and brachytherapy. Therefore, after the components of category one are configured as discussed with respect to blocks 602, 604, 606, and 608, the operator must determine whether to perform interstitial laser therapy or brachytherapy, as indicated by block 610. It should be appreciated that this determination dictates which of the components of category two are used first. If the operator wishes to perform interstitial laser therapy, the operator connects the laser optical fiber of category two to the laser energy source of category two and inserts the fiber in the energy probe, as indicated by block 612. The operator additionally configures the thermistor controller to send a plurality of signals indicating a plurality of detected temperatures to the computer, as indicated by block 614. Finally, the operator activates the laser energy source, which emits laser energy that is transmitted through the laser optical fiber and applied to the tumor mass, until a predefined temperature or set of temperatures is reached in the tissue adjacent to the tumor mass, as indicated by block 616. In an alternative embodiment, the laser energy source is configured to emit laser energy until a predefined amount of energy has been applied to the tumor mass.
Referring now to
Referring again to
Referring again to
It should be appreciated that in various embodiments, the process illustrated by portions 600a and 600b includes performing each of interstitial laser therapy and brachytherapy more than once, until the operator determines that the appropriate amount and type of therapeutic energy has been applied to the tumor mass.
In the illustrated embodiment, the connector box 24 includes a plurality of sockets 26 and 28 and at least one fiber optic cable connector 30. The sockets 26 and 28 are labeled Energy Probe and Sensing Probe, respectively. In an alternative embodiment, the connector box includes two or more fiber optic cable connectors such as connector 30, and the umbilical cable includes at least two optical fibers for connecting the connectors such as connector 30 to a plurality of energy sources configured to emit optical energy located remotely from the mammography unit 12.
Referring now to
The energy probe 100 also includes at least one sensor 100e. In the illustrated embodiment, the sensor 100e is connected to an energy probe connector 100d by way of a sensor wire 100c. In one embodiment, the sensor is a thermistor and is configured to detect a resistance and to send an electrical signal to the energy probe connector 100d indicative of a detected temperature at the tip of the energy probe 100. In another embodiment, the sensor 100e is a dosimeter configured to measure a dosage amount at the tip of the energy probe 100. In various embodiments, the energy probe includes a plurality of sensors such as sensor 100e for measuring temperature and dosage at the tip of the energy probe. It should be appreciated that in these embodiments, the electronic signals indicating a detected temperature and/or dosage for each of the sensors such as sensor 100e travel through the sensor wire 100c and into the connector 100d.
The energy probe is configured to be insertable through at least one probe holder, as discussed in detail below. The energy probe is also configured such that when the stylet 100b is removed from the cannula 100a, at least one optical fiber is insertable in the energy probe 100. In various embodiments, the cannula 100a of the probe 100 is further configured to enable an optical fiber and a volume of liquid to be positioned in the probe. In various embodiments, the liquid is saline and functions as a heat-transfer medium, as discussed below.
As discussed above, in the embodiment of the energy probe 100 illustrated in
The sensing probe further includes a plurality of sensors 102d. In one embodiment, the sensors 102d are thermistors configured to sense a plurality of resistances. In this embodiment, each thermistor 102d is connected by a conductor (not shown) to the sensing probe wire 102a, which in turn communicates the signals indicative of detected resistances to the connector 102b.
In another embodiment, the sensors 102d are a plurality of dosimeters configured to measure a plurality of charge differences between two electrodes. In this embodiment, each of the sensors 102d is connected by an appropriate conductor to the sensor wire 102a. The conductors are configured to send electronic signals indicative of a plurality of charge differences to the connector 102b. In various embodiments, the conductors are also configured to deliver electrical charge to two electrodes of each dosimeter 102d to maintain any required charge difference between the electrodes.
In various embodiments, the sensors 102d include a plurality of thermistors for measuring a plurality of temperatures and a plurality of dosimeters for measuring a plurality of dosage amounts. In this embodiment, it should be appreciated that a single sensing probe enables an operator to determine the amount of energy applied to a tumor based on the temperature of tissue adjacent to the tumor and based on the dosage amount received by tissue adjacent to the tumor. Thus, a sensing probe 102 including at least one dosimeter and at least one thermistor enables an operator to perform both interstitial laser therapy and brachytherapy.
The sensing probe is configured to be insertable in at least one probe holder, as discussed below. In this embodiment, the sensing probe is further configured to be positioned with respect to the energy probe based on the plurality of evenly spaced-apart marks 102c of the sensing probe. The sensing probe is also configured to include a trocar or other appropriate structure on the tip of the probe such that pressure applied to the sensing probe enables the sensing probe to puncture the skin such that the plurality of sensors 102e are positionable adjacent to a percutaneous tumor.
In an alternative embodiment, the therapeutic system disclosed herein includes at least two sensing probes such as sensing probe 102 wherein at least one sensing probe is a thermal probe and wherein at least one sensing probe is a dosage probe. In this embodiment, the at least one thermal probe includes one or more thermistors for measuring one or more temperatures of tissue adjacent to the tissue of interest, and the at least one dosage probe includes one or more dosimeters for measuring one or more dosage amounts of tissue adjacent to the tissue of interest.
In the illustrated embodiment, the energy probe 100 is positioned in the tumor mass 10 (which, as noted above, is illustrated as a saline bag). The probe holders 50 are configured to be rotatably insertable in the probe holder attachments 16a and 16b. In the illustrated embodiment, two probe holders 50 thus position the energy probe with respect to the tumor mass 10. In the illustrated embodiment, the energy probe 100 includes at least one thermistor and at least one dosimeter positioned near the tip of the energy probe. The energy probe wire 100c is configured to be connectable to the umbilical box such that a plurality of conductors within the energy probe wire 100c enable electrical signals to be sent from the at least one dosimeter and the at least one thermistor to the connector box 24. As illustrated, the energy probe wire 100c is connected to the connector box 24 by way of the energy probe socket 26. It should be appreciated that at least one wire of the umbilical cable 22 is configured to further send these electrical signals to the appropriate energy controller 240 or 250.
The probe holders 50 are further configured to position the sensing probe 102 with respect to the tumor mass 10. In the illustrated embodiment, the sensing probe 102 includes a plurality of thermistors and a plurality of dosimeters 102d (not shown) mounted near the end of the sensing probe inserted in the tissue adjacent to the tumor mass. Moreover, the sensing probe 102 includes a sensing probe wire 102a which includes a plurality of conductors for sending electrical signals indicating a plurality of temperatures or a plurality of dosage amounts to the connector box 24. In the illustrated embodiment, a single wire 102a includes each of the conductors for sending a signal from each dosimeter and each thermistor. As illustrated, the sensing probe wire 102a is configured to be connected to the connector box 24 by way of sensing probe socket 28. It should be appreciated that at least one wire of the umbilical cable 22 is configured send these electrical signals to the appropriate energy controller 240 or 250.
The configuration of the components of the disclosed therapeutic system illustrated in
It should be further appreciated that the disclosed therapeutic system, illustrated in
It should thus be appreciated that because the disclosed brachytherapy treatment and apparatus is utilized in conjunction with interstitial laser therapy as described herein, no balloon or other device is needed to maintain the integrity of any cavity—indeed, no cavity is formed during the interstitial laser therapy. Thus, the disclosed apparatus enables delivery of uniform x-ray or other therapeutic energy during a brachytherapy treatment using a substantially simplified device and immediately following another therapy, such as interstitial laser therapy. It should be further appreciated that the apparatus disclosed herein is not limited to the apparatus illustrated in FIG. 7B—rather, the apparatus of
It should be appreciated that the present disclosure is not limited to a therapeutic system for performing interstitial laser energy therapy and brachytherapy, and particularly, is not limited to a therapeutic system for applying laser energy and x-ray energy to a tumor mass in a breast. The present disclosure may apply to a variety of different non-surgical treatments for the destruction of a variety of different tumor masses.
In various embodiments, certain components of the system disclosed herein are usable to deliver various combinations of x-ray energy, laser energy, and other types of therapeutic energy to tissue to be treated during a single treatment. In one embodiment, the single treatment includes delivery of therapeutic energy, but does not include further removal of tissue to be treated. In another embodiment, the system disclosed herein is usable in conjunction with, in combination with, or coincident to known procedures for surgical excision of tissue to enhance the results of a single treatment. In an example embodiment, certain components of the disclosed system are usable coincident to a known lumpectomy procedure to treat tissue and to enhance the results obtained from such treatment. In other embodiments, the components of the system disclosed herein are usable to perform other types of surgical excision of tissue known to one of ordinary skill in the art.
It should be understood that modifications and variations may be effected without departing from the scope of the novel concepts of the present disclosure, and it should be understood that this application is to be limited only by the scope of the appended claims.
This application is a non-provisional application of, claims priority to, and the benefit of U.S. Provisional Patent Application No. 61/177,861, filed May 13, 2009, the entire contents of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4190461 | Hedger | Feb 1980 | A |
4510924 | Gray | Apr 1985 | A |
4763671 | Goffinet | Aug 1988 | A |
4815449 | Horowitz | Mar 1989 | A |
4976680 | Hayman et al. | Dec 1990 | A |
5084001 | Van't Hooft et al. | Jan 1992 | A |
5141487 | Liprie | Aug 1992 | A |
5153900 | Nomikos et al. | Oct 1992 | A |
5169396 | Dowlatshahi et al. | Dec 1992 | A |
5222953 | Dowlatshahi | Jun 1993 | A |
5339812 | Hardy et al. | Aug 1994 | A |
5411477 | Saab | May 1995 | A |
5428658 | Oettinger et al. | Jun 1995 | A |
5429582 | Williams | Jul 1995 | A |
5569240 | Dowlatshahi et al. | Oct 1996 | A |
5695479 | Jagpal | Dec 1997 | A |
5713828 | Coniglione | Feb 1998 | A |
5807395 | Mulier et al. | Sep 1998 | A |
5853366 | Dowlatshahi | Dec 1998 | A |
5868757 | Koutrouvelis | Feb 1999 | A |
5997463 | Cutrer | Dec 1999 | A |
6048299 | Hoffmann | Apr 2000 | A |
6066083 | Slater et al. | May 2000 | A |
6083148 | Williams | Jul 2000 | A |
6086942 | Carden, Jr. et al. | Jul 2000 | A |
6099458 | Robertson | Aug 2000 | A |
6106517 | Zupkas | Aug 2000 | A |
6129670 | Burdette et al. | Oct 2000 | A |
6132359 | Bolenbaugh | Oct 2000 | A |
6159141 | Apple et al. | Dec 2000 | A |
6163947 | Coniglione | Dec 2000 | A |
6179768 | Loffler et al. | Jan 2001 | B1 |
6196963 | Williams | Mar 2001 | B1 |
6196964 | Loffler et al. | Mar 2001 | B1 |
6210312 | Nagy | Apr 2001 | B1 |
6210315 | Andrews et al. | Apr 2001 | B1 |
6213932 | Schmidt | Apr 2001 | B1 |
6213976 | Trerotola | Apr 2001 | B1 |
6221003 | Sierocuk et al. | Apr 2001 | B1 |
6224536 | Pike | May 2001 | B1 |
6248057 | Mavity et al. | Jun 2001 | B1 |
6251059 | Apple et al. | Jun 2001 | B1 |
6267718 | Vitali et al. | Jul 2001 | B1 |
6285735 | Sliski et al. | Sep 2001 | B1 |
6287249 | Tam et al. | Sep 2001 | B1 |
6299856 | DeVore et al. | Oct 2001 | B1 |
6315979 | Simon et al. | Nov 2001 | B1 |
6319188 | Lovoi | Nov 2001 | B1 |
6320932 | Dinsmore | Nov 2001 | B2 |
6320935 | Shinar et al. | Nov 2001 | B1 |
6327490 | Spetz | Dec 2001 | B1 |
6347443 | Coniglione | Feb 2002 | B2 |
6352500 | Halpern | Mar 2002 | B1 |
6352501 | Urick | Mar 2002 | B1 |
6358195 | Green et al. | Mar 2002 | B1 |
6360116 | Jackson, Jr. et al. | Mar 2002 | B1 |
6361487 | Green et al. | Mar 2002 | B1 |
6366796 | Yanof et al. | Apr 2002 | B1 |
6387034 | Lee | May 2002 | B1 |
6390967 | Forman et al. | May 2002 | B1 |
6390968 | Harmon | May 2002 | B1 |
6391026 | Hung et al. | May 2002 | B1 |
6391279 | Singh et al. | May 2002 | B1 |
6398711 | Green et al. | Jun 2002 | B1 |
6402677 | Jacobs | Jun 2002 | B1 |
6413204 | Winkler et al. | Jul 2002 | B1 |
6415921 | Ye et al. | Jul 2002 | B2 |
6416531 | Chen | Jul 2002 | B2 |
6419621 | Sioshansi et al. | Jul 2002 | B1 |
6419866 | Karl et al. | Jul 2002 | B1 |
6436026 | Sioshansi et al. | Aug 2002 | B1 |
6450937 | Mercereau et al. | Sep 2002 | B1 |
6450938 | Miller | Sep 2002 | B1 |
6471631 | Slater et al. | Oct 2002 | B1 |
6477426 | Fenn et al. | Nov 2002 | B1 |
6493419 | Dinsmore | Dec 2002 | B1 |
6494835 | Ciezki et al. | Dec 2002 | B1 |
6500108 | Sorensen et al. | Dec 2002 | B1 |
6527693 | Munro, III et al. | Mar 2003 | B2 |
6530873 | Lee | Mar 2003 | B1 |
6530875 | Taylor et al. | Mar 2003 | B1 |
6537195 | Forman | Mar 2003 | B2 |
6539247 | Spetz | Mar 2003 | B2 |
6551232 | Rivard | Apr 2003 | B1 |
6554756 | Schaart | Apr 2003 | B1 |
6558309 | Hogendijk et al. | May 2003 | B2 |
6561967 | Schmidt | May 2003 | B2 |
6572526 | Ford | Jun 2003 | B1 |
6575888 | Zamora et al. | Jun 2003 | B2 |
6579262 | Mick et al. | Jun 2003 | B1 |
6582354 | Ellard | Jun 2003 | B2 |
6582417 | Ledesma et al. | Jun 2003 | B1 |
6585633 | Vitali et al. | Jul 2003 | B2 |
6589173 | Mitragotri | Jul 2003 | B1 |
6589502 | Coniglione et al. | Jul 2003 | B1 |
6603988 | Dowlatshahi | Aug 2003 | B2 |
6607476 | Barnhart | Aug 2003 | B1 |
6607478 | Williams | Aug 2003 | B2 |
6608277 | Spooner et al. | Aug 2003 | B2 |
6610013 | Fenster et al. | Aug 2003 | B1 |
6615070 | Lee | Sep 2003 | B2 |
6626817 | Luth | Sep 2003 | B2 |
6632176 | McIntire et al. | Oct 2003 | B2 |
6638205 | Chan et al. | Oct 2003 | B1 |
6638206 | Green et al. | Oct 2003 | B2 |
6639237 | Pedersen et al. | Oct 2003 | B2 |
6641518 | Wolfson et al. | Nov 2003 | B2 |
6648811 | Sierocuk et al. | Nov 2003 | B2 |
6652442 | Gatto | Nov 2003 | B2 |
6656107 | Pedersen et al. | Dec 2003 | B1 |
6659105 | Burbank et al. | Dec 2003 | B2 |
6659933 | Asano | Dec 2003 | B2 |
6669621 | O'Hara et al. | Dec 2003 | B2 |
6673006 | Winkler | Jan 2004 | B2 |
6676590 | Urick et al. | Jan 2004 | B1 |
6676595 | Delfino | Jan 2004 | B1 |
6676658 | Burbank et al. | Jan 2004 | B2 |
6679824 | Reed et al. | Jan 2004 | B1 |
6682471 | Steele, Sr. et al. | Jan 2004 | B2 |
6685618 | Tam et al. | Feb 2004 | B2 |
6685619 | Halpern et al. | Feb 2004 | B2 |
6689043 | McIntire et al. | Feb 2004 | B1 |
6689811 | Koumenis et al. | Feb 2004 | B2 |
6692587 | Ro et al. | Feb 2004 | B2 |
6695760 | Winkler et al. | Feb 2004 | B1 |
6695787 | Hogendijk et al. | Feb 2004 | B2 |
6699171 | Harmon | Mar 2004 | B2 |
6701175 | Dowlatshahi | Mar 2004 | B2 |
6703375 | Buchsbaum et al. | Mar 2004 | B2 |
6706014 | Banik et al. | Mar 2004 | B2 |
6706699 | Wang et al. | Mar 2004 | B2 |
6709380 | Green et al. | Mar 2004 | B2 |
6709381 | Munro, III | Mar 2004 | B2 |
6712782 | Ford | Mar 2004 | B2 |
6712816 | Hung et al. | Mar 2004 | B2 |
6713462 | Metcalf, III et al. | Mar 2004 | B2 |
6716156 | Menuhr et al. | Apr 2004 | B2 |
6727225 | Wiley | Apr 2004 | B2 |
6730013 | Shank et al. | May 2004 | B1 |
6746392 | Stiger et al. | Jun 2004 | B2 |
6746393 | Mawad | Jun 2004 | B2 |
6746465 | Diederich et al. | Jun 2004 | B2 |
6746661 | Kaplan | Jun 2004 | B2 |
6749553 | Brauckman et al. | Jun 2004 | B2 |
6749555 | Winkler et al. | Jun 2004 | B1 |
6752752 | Geitz | Jun 2004 | B2 |
6752753 | Hoskins et al. | Jun 2004 | B1 |
6755775 | Kalas et al. | Jun 2004 | B2 |
6761679 | Sajo et al. | Jul 2004 | B2 |
6761680 | Terwilliger et al. | Jul 2004 | B2 |
6770021 | Halpern | Aug 2004 | B2 |
6773390 | McDaniel | Aug 2004 | B2 |
6778850 | Adler et al. | Aug 2004 | B1 |
6786858 | Terwilliger et al. | Sep 2004 | B2 |
6788977 | Fenn et al. | Sep 2004 | B2 |
6790170 | Moody et al. | Sep 2004 | B2 |
6792073 | Deasy et al. | Sep 2004 | B2 |
6796936 | Slater et al. | Sep 2004 | B2 |
6799075 | Chornenky et al. | Sep 2004 | B1 |
6800055 | Amols et al. | Oct 2004 | B2 |
6809517 | McGee et al. | Oct 2004 | B2 |
6811779 | Rockwell et al. | Nov 2004 | B2 |
6817995 | Halpern | Nov 2004 | B1 |
6820318 | Terwilliger et al. | Nov 2004 | B2 |
6824507 | Miller | Nov 2004 | B2 |
6824773 | Wiley | Nov 2004 | B2 |
6837844 | Ellard et al. | Jan 2005 | B1 |
6846282 | Ford | Jan 2005 | B1 |
6846283 | Green et al. | Jan 2005 | B2 |
6847700 | Mitra et al. | Jan 2005 | B1 |
6847838 | Macey et al. | Jan 2005 | B1 |
6856668 | Thomson et al. | Feb 2005 | B1 |
6861044 | Simon et al. | Mar 2005 | B2 |
6863654 | Zappala et al. | Mar 2005 | B2 |
6865412 | Dowlatshahi | Mar 2005 | B2 |
6866624 | Chornenky et al. | Mar 2005 | B2 |
6867305 | Danishefsky et al. | Mar 2005 | B2 |
6869390 | Elliott et al. | Mar 2005 | B2 |
6869588 | Weller et al. | Mar 2005 | B2 |
6878697 | Metcalf, III et al. | Apr 2005 | B2 |
6890950 | Boothman et al. | May 2005 | B2 |
6910999 | Chin et al. | Jun 2005 | B2 |
6919067 | Filler et al. | Jul 2005 | B2 |
6921769 | Danishefsky et al. | Jul 2005 | B2 |
6923754 | Lubock | Aug 2005 | B2 |
6949064 | Lowery et al. | Sep 2005 | B2 |
6953426 | Barber et al. | Oct 2005 | B2 |
6955640 | Sanders et al. | Oct 2005 | B2 |
6955641 | Lubock | Oct 2005 | B2 |
6957108 | Turner et al. | Oct 2005 | B2 |
6960572 | Shakespeare et al. | Nov 2005 | B2 |
6965847 | Wessol et al. | Nov 2005 | B2 |
6967198 | Benedict et al. | Nov 2005 | B2 |
6976949 | Winkler et al. | Dec 2005 | B2 |
6985557 | Jaafar | Jan 2006 | B2 |
6986880 | Coniglione et al. | Jan 2006 | B2 |
6987835 | Lovoi | Jan 2006 | B2 |
6989486 | Lovoi et al. | Jan 2006 | B2 |
6994688 | Brauckman et al. | Feb 2006 | B2 |
6997861 | Halpern et al. | Feb 2006 | B2 |
6997862 | Terwilliger et al. | Feb 2006 | B2 |
7008368 | Terwilliger et al. | Mar 2006 | B2 |
7008633 | Yang et al. | Mar 2006 | B2 |
7009054 | Wang et al. | Mar 2006 | B2 |
7018371 | Forman | Mar 2006 | B2 |
7019139 | Metcalf, III et al. | Mar 2006 | B2 |
7025717 | Tarone et al. | Apr 2006 | B2 |
7031432 | Geitz | Apr 2006 | B2 |
7037252 | Flanagan et al. | May 2006 | B2 |
7041046 | Forman | May 2006 | B2 |
7041047 | Gellman et al. | May 2006 | B2 |
7041048 | Drobnik et al. | May 2006 | B2 |
7041109 | Dowlatshahi | May 2006 | B2 |
7048717 | Frassica | May 2006 | B1 |
7060020 | Terwilliger et al. | Jun 2006 | B2 |
7064211 | Kowalczyk et al. | Jun 2006 | B2 |
7066872 | Waksman et al. | Jun 2006 | B2 |
7067475 | Cerretti et al. | Jun 2006 | B2 |
7070554 | White et al. | Jul 2006 | B2 |
7074291 | Terwilliger et al. | Jul 2006 | B2 |
7074408 | Fanslow, III et al. | Jul 2006 | B2 |
7077800 | Gross et al. | Jul 2006 | B2 |
7083566 | Tornes et al. | Aug 2006 | B2 |
7091343 | Bebbington et al. | Aug 2006 | B2 |
7094198 | Terwilliger et al. | Aug 2006 | B2 |
7107089 | Lee | Sep 2006 | B2 |
7109505 | Sliski et al. | Sep 2006 | B1 |
7115589 | Weigele et al. | Oct 2006 | B2 |
7115651 | Danishefsky et al. | Oct 2006 | B2 |
7118523 | Loffler et al. | Oct 2006 | B2 |
7118524 | Rivard | Oct 2006 | B2 |
7122552 | Ledford | Oct 2006 | B2 |
7127033 | Lovoi et al. | Oct 2006 | B2 |
7130380 | Lovoi et al. | Oct 2006 | B2 |
7131942 | Taylor et al. | Nov 2006 | B2 |
7132427 | Wang et al. | Nov 2006 | B2 |
7132533 | Benedict et al. | Nov 2006 | B2 |
7158612 | Rusch et al. | Jan 2007 | B2 |
7171253 | Dowlatshahi | Jan 2007 | B2 |
7175635 | Loser | Feb 2007 | B2 |
7175849 | Baum et al. | Feb 2007 | B2 |
7179826 | Bebbington et al. | Feb 2007 | B2 |
7179912 | Halbrook et al. | Feb 2007 | B2 |
7182726 | Williams et al. | Feb 2007 | B2 |
7187800 | Hibbard | Mar 2007 | B2 |
7190895 | Groves et al. | Mar 2007 | B1 |
7192972 | Kowalczyk et al. | Mar 2007 | B2 |
7196090 | Connolly et al. | Mar 2007 | B2 |
7198783 | Morris et al. | Apr 2007 | B2 |
7200203 | Cocks et al. | Apr 2007 | B2 |
7201715 | Burdette et al. | Apr 2007 | B2 |
7201890 | Goldenberg | Apr 2007 | B2 |
7201906 | Cheung | Apr 2007 | B2 |
7204986 | Cheung | Apr 2007 | B2 |
7204987 | Cheung | Apr 2007 | B2 |
7204988 | Cheung | Apr 2007 | B2 |
7208158 | Cheung | Apr 2007 | B2 |
7208500 | Lou et al. | Apr 2007 | B2 |
7208517 | Winn et al. | Apr 2007 | B1 |
7211039 | Lamoureux | May 2007 | B2 |
7211055 | Diederich et al. | May 2007 | B2 |
7214368 | Rasmussen et al. | May 2007 | B2 |
7214377 | Cheung | May 2007 | B2 |
7217242 | Alam et al. | May 2007 | B2 |
7228579 | Tidwell | Jun 2007 | B2 |
7252630 | Terwilliger et al. | Aug 2007 | B2 |
7267643 | Koster et al. | Sep 2007 | B2 |
7313430 | Urquhart et al. | Dec 2007 | B2 |
7322928 | Reed et al. | Jan 2008 | B2 |
7322929 | Lovoi | Jan 2008 | B2 |
7329242 | Peery | Feb 2008 | B2 |
7344490 | Shaw et al. | Mar 2008 | B2 |
7344533 | Pearson et al. | Mar 2008 | B2 |
7351193 | Forman et al. | Apr 2008 | B2 |
7354391 | Stubbs | Apr 2008 | B2 |
7357770 | Cutrer et al. | Apr 2008 | B1 |
7361134 | Rozenfeld et al. | Apr 2008 | B2 |
7361135 | Drobnik et al. | Apr 2008 | B2 |
7396354 | Rychnovsky et al. | Jul 2008 | B2 |
7399977 | Rink et al. | Jul 2008 | B2 |
7410458 | Bray et al. | Aug 2008 | B2 |
7419487 | Johnson et al. | Sep 2008 | B2 |
7422588 | Mulier et al. | Sep 2008 | B2 |
7425194 | Baltas et al. | Sep 2008 | B2 |
7725155 | Dowlatshahi | May 2010 | B2 |
20010055589 | Smilowitz et al. | Dec 2001 | A1 |
20020010500 | Chen | Jan 2002 | A1 |
20020010502 | Trachtenberg | Jan 2002 | A1 |
20020077521 | Green et al. | Jun 2002 | A1 |
20020091315 | Spetz | Jul 2002 | A1 |
20020151778 | Dowlatshahi | Oct 2002 | A1 |
20020169354 | Munro, III | Nov 2002 | A1 |
20020169410 | Ford | Nov 2002 | A1 |
20020177748 | Munro, III | Nov 2002 | A1 |
20020193654 | Mawad | Dec 2002 | A1 |
20030018233 | Miller | Jan 2003 | A1 |
20030045769 | Kalas et al. | Mar 2003 | A1 |
20030083566 | Dowlatshahi | May 2003 | A1 |
20030092956 | Williams | May 2003 | A1 |
20030092958 | Terwilliger et al. | May 2003 | A1 |
20030097035 | Tucker et al. | May 2003 | A1 |
20030130711 | Pearson et al. | Jul 2003 | A1 |
20030153850 | Davis et al. | Aug 2003 | A1 |
20030158515 | Gonzalez et al. | Aug 2003 | A1 |
20030171637 | Terwilliger et al. | Sep 2003 | A1 |
20030171638 | Schaart | Sep 2003 | A1 |
20030176759 | Hogendijk et al. | Sep 2003 | A1 |
20030212302 | Rozenfeld et al. | Nov 2003 | A1 |
20030229282 | Burdette et al. | Dec 2003 | A1 |
20030233136 | Williams et al. | Dec 2003 | A1 |
20040010290 | Schroeppel et al. | Jan 2004 | A1 |
20040068157 | Gellman et al. | Apr 2004 | A1 |
20040077919 | Drobnik et al. | Apr 2004 | A1 |
20040102671 | Terwilliger et al. | May 2004 | A1 |
20040106840 | Kindlein et al. | Jun 2004 | A1 |
20040109823 | Kaplan | Jun 2004 | A1 |
20040111004 | Loffler et al. | Jun 2004 | A1 |
20040116767 | Lebovic et al. | Jun 2004 | A1 |
20040116914 | Dowlatshahi | Jun 2004 | A1 |
20040133195 | Solomon | Jul 2004 | A1 |
20040138515 | White et al. | Jul 2004 | A1 |
20040152973 | Lee | Aug 2004 | A1 |
20040162458 | Green et al. | Aug 2004 | A1 |
20040186340 | Reed et al. | Sep 2004 | A1 |
20040192998 | Brauckman et al. | Sep 2004 | A1 |
20040210101 | Winkler | Oct 2004 | A1 |
20040225176 | Flanagan et al. | Nov 2004 | A1 |
20040230087 | Terwilliger et al. | Nov 2004 | A1 |
20040243200 | Turner et al. | Dec 2004 | A1 |
20040254418 | Munro et al. | Dec 2004 | A1 |
20050000525 | Klimberg et al. | Jan 2005 | A1 |
20050004507 | Schroeppel et al. | Jan 2005 | A1 |
20050011526 | Forman et al. | Jan 2005 | A1 |
20050027156 | Pulido et al. | Feb 2005 | A1 |
20050027196 | Fitzgerald | Feb 2005 | A1 |
20050031648 | Brin et al. | Feb 2005 | A1 |
20050049508 | Forman et al. | Mar 2005 | A1 |
20050070753 | Forman et al. | Mar 2005 | A1 |
20050075529 | Pedersen et al. | Apr 2005 | A1 |
20050080313 | Stewart et al. | Apr 2005 | A1 |
20050080340 | Stewart et al. | Apr 2005 | A1 |
20050085681 | Stubbs et al. | Apr 2005 | A1 |
20050096515 | Geng | May 2005 | A1 |
20050101824 | Stubbs | May 2005 | A1 |
20050101825 | Winkler et al. | May 2005 | A1 |
20050101826 | Bray et al. | May 2005 | A1 |
20050107653 | Patrick et al. | May 2005 | A1 |
20050119725 | Wang et al. | Jun 2005 | A1 |
20050124844 | Forman | Jun 2005 | A1 |
20050184424 | Ferguson | Aug 2005 | A1 |
20050187422 | Maschke | Aug 2005 | A1 |
20050191207 | Terwilliger et al. | Sep 2005 | A1 |
20050251235 | Schlorff et al. | Nov 2005 | A1 |
20050261541 | Henderson et al. | Nov 2005 | A1 |
20050267319 | White et al. | Dec 2005 | A1 |
20050277802 | Larsen et al. | Dec 2005 | A1 |
20060017009 | Rink et al. | Jan 2006 | A1 |
20060023843 | Kusch | Feb 2006 | A1 |
20060058568 | Gross et al. | Mar 2006 | A1 |
20060063961 | Drobnik et al. | Mar 2006 | A1 |
20060063962 | Drobnik et al. | Mar 2006 | A1 |
20060067467 | Chornenky et al. | Mar 2006 | A1 |
20060069298 | Terwilliger et al. | Mar 2006 | A1 |
20060074303 | Chornenky et al. | Apr 2006 | A1 |
20060089520 | Terwilliger et al. | Apr 2006 | A1 |
20060100475 | White et al. | May 2006 | A1 |
20060100476 | Biscotti | May 2006 | A1 |
20060111605 | Larsen et al. | May 2006 | A1 |
20060116546 | Eng | Jun 2006 | A1 |
20060122452 | van't Hooft | Jun 2006 | A1 |
20060167332 | Bray | Jul 2006 | A1 |
20060173232 | Lovoi et al. | Aug 2006 | A1 |
20060173233 | Lovoi | Aug 2006 | A1 |
20060173235 | Lim et al. | Aug 2006 | A1 |
20060173236 | White et al. | Aug 2006 | A1 |
20060183959 | Sioshansi et al. | Aug 2006 | A1 |
20060183960 | Sioshansi et al. | Aug 2006 | A1 |
20060184018 | Cox et al. | Aug 2006 | A1 |
20060224035 | Russell et al. | Oct 2006 | A1 |
20060235260 | Mourtada et al. | Oct 2006 | A1 |
20060235365 | Terwilliger et al. | Oct 2006 | A1 |
20060241332 | Klein et al. | Oct 2006 | A1 |
20060241727 | Dowlatshahi | Oct 2006 | A1 |
20070015837 | Kun et al. | Jan 2007 | A1 |
20070016062 | Park et al. | Jan 2007 | A1 |
20070021643 | Lamoureux et al. | Jan 2007 | A1 |
20070027352 | Mourtada et al. | Feb 2007 | A1 |
20070038014 | Cox et al. | Feb 2007 | A1 |
20070049786 | Edmundson | Mar 2007 | A1 |
20070055090 | Neustadter et al. | Mar 2007 | A1 |
20070074347 | Coppens et al. | Apr 2007 | A1 |
20070075277 | Smith et al. | Apr 2007 | A1 |
20070084474 | Rivard | Apr 2007 | A1 |
20070100229 | Dowlatshahi | May 2007 | A1 |
20070106108 | Hermann et al. | May 2007 | A1 |
20070123815 | Mark | May 2007 | A1 |
20070135873 | Johansson et al. | Jun 2007 | A1 |
20070140426 | Axelrod et al. | Jun 2007 | A1 |
20070142694 | Cutrer et al. | Jun 2007 | A1 |
20070142695 | White et al. | Jun 2007 | A1 |
20070149571 | Stein et al. | Jun 2007 | A1 |
20070167665 | Hermann et al. | Jul 2007 | A1 |
20070173680 | Rioux et al. | Jul 2007 | A1 |
20070219488 | Francescatti | Sep 2007 | A1 |
20070270627 | Cutrer et al. | Nov 2007 | A1 |
20070288075 | Dowlatshahi | Dec 2007 | A1 |
20080004478 | Francescatti et al. | Jan 2008 | A1 |
20080004524 | Francescatti et al. | Jan 2008 | A1 |
20080004543 | Davies | Jan 2008 | A1 |
20080009658 | Smith et al. | Jan 2008 | A1 |
20080009659 | Smith et al. | Jan 2008 | A1 |
20080071132 | Lamoureux et al. | Mar 2008 | A1 |
20080086026 | Keppel et al. | Apr 2008 | A1 |
20080091056 | Kaplan | Apr 2008 | A1 |
20080103104 | Moore et al. | May 2008 | A1 |
20080118518 | Cirrito et al. | May 2008 | A1 |
20080154085 | Jervis et al. | Jun 2008 | A1 |
20080154086 | Stubbs | Jun 2008 | A1 |
20080177127 | Allan et al. | Jul 2008 | A1 |
20080185314 | Tomasello et al. | Aug 2008 | A1 |
20080188841 | Tomasello et al. | Aug 2008 | A1 |
20080188842 | Tomasello et al. | Aug 2008 | A1 |
20080194985 | Nicoson et al. | Aug 2008 | A1 |
20080208052 | LePivert et al. | Aug 2008 | A1 |
20080214887 | Heanue et al. | Sep 2008 | A1 |
20080221384 | Chi Sing et al. | Sep 2008 | A1 |
20080221443 | Ritchie et al. | Sep 2008 | A1 |
20080221444 | Ritchie et al. | Sep 2008 | A1 |
20080221478 | Ritchie et al. | Sep 2008 | A1 |
20080221479 | Ritchie et al. | Sep 2008 | A1 |
20080293994 | Francescatti et al. | Nov 2008 | A1 |
20080300443 | Lovoi | Dec 2008 | A1 |
20080300445 | Francescatti et al. | Dec 2008 | A1 |
20080306322 | Jervis et al. | Dec 2008 | A1 |
20080306323 | Jervis et al. | Dec 2008 | A1 |
20090030258 | Axelrod et al. | Jan 2009 | A1 |
20100222647 | Hashimshony et al. | Sep 2010 | A1 |
Entry |
---|
A fibre optic scintillator dosimeter for absorbed dose measurements of low-energy X-ray-emitting brachytherapy sources, Sliski, Alan et al., Radiation Protection Dosimetry, Jun. 16, 2006. |
A Novel real-time dosimetry technique based on radiation-induced surface activation, H. Tomozawa et al., Apr. 27, 2006. |
Advanced X-Ray Technology, Inc., website, downloaded from http://www.axt-medical.com/products/softray, Jan. 15, 2008. |
Advanced X-Ray Technology Devices—Description, website, http://www.axt-medical.com, downloaded Nov. 29, 2007. |
Brachytherapy—definition, RadiologyInfo website, http://www.radiologyinfo/org/en/info.cfm?pg=brachy&bhcp=1, downloaded Nov. 29, 2007. |
Brachytherapy—Wikipedia definition, website, http://en.wikipedia.org/wiki/Brachytherapy, downloaded Nov. 29, 2007. |
Breast Cancer—defintion, RadiologyInfo website, http://www.radiologyinfo/org/en/info.cfm?pg=breastcancer , downloaded Nov. 29, 2007. |
Critical Technology for In-Space Application of Nuclear Thermal Propulsion—Real-Time Micro-Miniature Dosimeter, NASA SBIR 2005 Solicitation, website, http://sbir.gsfc.nasa.gov/SBIR/abstracts/05/sbir/phase1/sbir-05-1-X10.03-8601.html, downloaded Nov. 29, 2007. |
Dosimeter—Wikipedia definition, website, http://en.wikipedia.org/wiki/Dosimeter, downloaded Nov. 29, 2007. |
Dosimetrists—definition, RadiologyInfo website, http://www.radiologyinfo.org/en/glossary/glossary1.cfm?Term=dosimetrist&bhcp=1, downloaded Nov. 29, 2007. |
HDR Brachytherapy Article, website, http://www.cancercenter.com/conventional-cancer-treatment/hdr-brachytherapy.cfm, website, downloaded Nov. 29, 2007. |
MammoSite 5-Day Target Radiation Therapy: How It Works, website, http://www.mammosite.com/breast-lumpectomy/ow-it-works.cfm, downloaded Nov. 29, 2007. |
Neutron Spectrometer, Real-Time Dosimeter and Methodology Using Three-Dimensional Optical Memory, website, http://otl.georgetown.edu/industry/inventions/moma430503.html, downloaded Nov. 29, 2007. |
Portable Waterphantom Scanning System, website, downloaded from http://www.multidata-systems.com/rtdwph.asp?wph=port, downloaded Nov. 29, 2007. |
RTD (Realtime Dosimetry System), website, downloaded from http://www.multidata-systems.com/rtd—prodpg.asp, downloaded Nov. 29, 2007. |
Source 1 X-Ray, website, downloaded from http://www.source1xray.com/glenbrook—detail.html, Jan. 15, 2008. |
Stereotactic-guided laser-induced interstitial thermotherapy (SLITT) in gliomas with interoperative morphologic monitoring in open MRI—Abstract, Lumenta, Christiano et al. (Proc. SPIE vol. 4156, Jan. 2001. |
Wallet Card Dosimeters, website, downloaded from http://www.stanforddosimetery.com/SIRAD/walletdosimeter.html, Nov. 29, 2007. |
X-ray scalpel—new device for target x-ray brachytherapy and stereotactic radiosurgery—Abstract, Gutman, George et al., Mar. 2007. |
Number | Date | Country | |
---|---|---|---|
20100292682 A1 | Nov 2010 | US |
Number | Date | Country | |
---|---|---|---|
61177861 | May 2009 | US |